"There appear to be two main clinical implications of our findings," Callaghan told Psychiatric News. "First, meth users and their caregivers need to know that chronic meth use may pose a risk for the development of Parkinson's
disease. However, it is important to note that most Parkinson's disease patients do not develop the disease because of meth
use. Secondly, while we note in our paper that our findings may not relate at all to the use of prescription amphetamine-type
stimulants (for example, for the treatment of attention-deficit/hyperactivity disorder), our findings do warrant further studies
examining the long-term neurological impact of prescription amphetamine-type stimulant use."